Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 2/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 10/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.39 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475571 | 1.00 | NPC1 (0.45) | NPC1RAB9AATMERN1PROKR1 | |
| SCHEMBL29475558 | 1.00 | NPC1 (0.45) | NPC1RAB9AATMERN1PROKR1 | |
| SCHEMBL30476675 | 1.00 | NPC1 (0.45) | NPC1RAB9AATMERN1PROKR1 | |
| SCHEMBL25319039 | 1.00 | NPC1 (0.45) | NPC1RAB9AATMERN1PROKR1 | |
| SCHEMBL29475595 | 1.00 | NPC1 (0.45) | NPC1RAB9AATMERN1PROKR1 | |
| SCHEMBL25319473 | 1.00 | NPC1 (0.45) | NPC1RAB9AATMERN1PROKR1 | |
| SCHEMBL25319847 | 0.95 | ERN1 (0.47) | NPC1RAB9AATMERN1FAAH | |
| SCHEMBL29475525 | 0.95 | ERN1 (0.47) | NPC1RAB9AATMERN1FAAH | |
| SCHEMBL25317544 | 0.93 | ERN1 (0.47) | NPC1RAB9AERN1PROKR1FAAH | |
| SCHEMBL29475606 | 0.93 | ERN1 (0.47) | NPC1RAB9AERN1PROKR1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | NPC1 652/4885RAB9A 3141/4885ATM 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.